IP Library Granted Patent US 8,114,434
Granted Patent B2
US 8,114,434 · App. 12/614,816 · Granted Feb 14, 2012

Diclofenac sodium patches for topical treatment of pain

Assignees: Tokuhon Corporation; SSP Co., Ltd.; Dojin Iyaku Kako Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,434
App. No.
12/614,816
Granted
Feb 14, 2012
Kind
B2
Abstract

The invention provides an analgesic anti-inflammatory patch of a hydrophobic type for topical application containing, in a Pressure Sensitive Adhesive(PSA), diclofenac sodium, pyrrolidone or a derivative thereof, a polyhydric alcohol fatty acid ester, and an organic acid. The patch exerts the following effects: (1) diclofenac sodium is effectively and continuously released from a Pressure Sensitive Adhesive(PSA) and percutaneously absorbed, thereby attaining sustained, excellent pharmaceutical and pharmacological effects; (2) the patch per se has high tackiness and safety; and (3) diclofenac sodium remains stable in the Pressure Sensitive Adhesive(PSA).

Claims (23)

1. A method of treating pain, comprising topically applying an analgesic anti-inflammatory Pressure Sensitive Adhesive (PSA) patch, comprising a soft support and a PSA layer on the soft support, to a subject in need thereof, wherein the PSA layer comprises

1 wt. % of diclofenac sodium,

2 to 4 wt. % of N-methyl-2-pyrrolidone,

2 wt. % of propylene glycol monocaprylate,

0.4 wt. % of citric acid,

28.5 to 38 wt % of a styrene-isoprene-styrene block copolymer,

2 to 4 wt % polyisobutylene,

12 to 25 wt % of an ester gum,

30 to 40 wt % of liquid paraffin, and

no added water.

2. The method of claim 1 , wherein the PSA layer further comprises 1-menthol.

3. The method of claim 2 , wherein the PSA layer contains 1 to 3 wt .% of the 1-menthol.

4. The method of claim 1 , wherein the PSA layer contains no 1-menthol.

5. The method of claim 1 , further comprising an anti-ageing agent.

6. The method of claim 1 , wherein the soft support does not permit permeation of the PSA layer through the back of the support.

7. The method of claim 1 , wherein the soft support is selected from the group consisting of woven fabrics, non-woven fabrics, plastic films, and films of a foamed blend of acrylic polymer or polystyrene-polybutadiene and polyisoprene.

8. The method of claim 1 , wherein the soft support is a plastic film selected from the group consisting of polyolefin film, polyvinyl alcohol film, vinyl chloride film, urethane alloy film, urethane-vinyl chloride copolymer film, and ethylene-vinyl acetate film.

9. The method of claim 8 , wherein the plastic film is a film of foamed blend of acrylic polymer or polystyrene-polybutadiene and polyisoprene.

10. The method of claim 1 , wherein the soft support has a thickness of about 1,000 μm or less.

11. The method of claim 1 , wherein the soft support has a thickness of 30-700 μm.

12. The method of claim 1 , wherein the patch is applied to the site of an inflamed joint.

13. The method of claim 1 , wherein the patch is applied to an inflamed site of the neck of the subject.

14. The method of claim 1 , wherein the patch is applied to an inflamed site of a muscle of the subject.

Assignments (1)
CHANGE OF ADDRESS Recorded Oct 5, 2018
From: SSP CO., LTD.
To: SSP CO., LTD.
Reel/Frame 047197/0129 →
Priority Claims (1)
JP 2001-154008 · May 23, 2001 · national
Continuity (2)
Continuation 10332978
Related Publication 20100055160A1 · Mar 4, 2010